Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Obstructive Hypertrophic Cardiomyopathy (oHCM): later-stage trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Obstructive Hypertrophic Cardiomyopathy (oHCM): 2 US clinical trials tracked, none currently recruiting.
Obstructive Hypertrophic Cardiomyopathy (oHCM) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Cytokinetics, running 1 of these trials.
Enrollment posture brief
Registry condition obstructive-hypertrophic-cardiomyopathy-ohcm
OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Obstructive Hypertrophic Cardiomyopathy (oHCM) has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Obstructive Hypertrophic Cardiomyopathy (oHCM) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Obstructive Hypertrophic Cardiomyopathy (oHCM) is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
Bristol-Myers Squibb
NCT07107373
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
Cytokinetics
NCT05186818
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Obstructive Hypertrophic Cardiomyopathy (oHCM) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Obstructive Hypertrophic Cardiomyopathy (oHCM) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Obstructive Hypertrophic Cardiomyopathy (oHCM) page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Obstructive Hypertrophic Cardiomyopathy (oHCM) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Cytokinetics sponsors the most Obstructive Hypertrophic Cardiomyopathy (oHCM) trials on record, review their full trial history before evaluating a specific study. See Cytokinetics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Obstructive Hypertrophic Cardiomyopathy (oHCM) condition card totals 2 registered trials; most-linked intervention Placebo to match aficamten; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.